On May 23, 2024 Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, reported multiple presentations at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held in Chicago from May 31-June 4, 2024 (Press release, Replimune, MAY 23, 2024, View Source [SID1234643615]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company has two abstracts selected for oral presentation, including an updated presentation of investigator-assessed 12-month data from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) plus nivolumab in anti-PD-1 failed melanoma, and another presentation showcasing data from the Phase 1 trial of RP2 combined with nivolumab in advanced uveal melanoma. In addition, RP1 and RP2 are also featured in three trial-in-progress posters.
Details for the presentations are as follows:
Oral data presentations
Abstract Title: Efficacy and safety of RP1 combined with nivolumab in patients with anti-PD-1 failed melanoma from the IGNYTE clinical trial. Data included in the presentation will be 12-month investigator-assessed data with a cutoff date of March 8, 2024, as compared to the abstract which includes 6-month investigator-assessed data. As previously disclosed, the topline 12-month primary analysis results by independent central review are expected later in Q2 2024.
Session Title: Melanoma/Skin Cancers
Date: June 3, 2024; 10:57-11:03 AM CDT
Location: S406
Abstract: 9517
Abstract Title: Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanoma.
Session Title: Melanoma/Skin Cancers
Date: June 3, 2024; 9:57-10:03 AM CDT
Location: S406
Abstract: 9511
Trial-in-progress poster presentations
Abstract Title: A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec (VO) combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti-PD-1 and anti-CTLA-4 therapy (IGNYTE-3).
Poster Session Title: Melanoma/Skin Cancers
Date: June 1, 2024, 1:30 PM-4:30 PM CDT
Location: Hall A, Poster Board 385b
Abstract: TPS9604
Abstract Title: An open-label, multicenter study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab combined with bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma
Poster Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Date: June 1, 2024, 1:30 PM-4:30 PM CDT
Location: Hall A, Poster Board 165b
Abstract: TPS4191
Abstract Title: IST: Trial in progress: A phase 1/2 study of Vusolimogene oderparepvec in primary melanoma (mel) to reduce the risk of sentinel lymph node (SLN) metastasis.
Poster Session Title: Melanoma/Skin Cancers
Date: June 1, 2024, 1:30 PM-4:30 PM CDT
Location: Hall A, Poster Board 390b
Abstract: TPS9614
About RP1
RP1 is Replimune’s lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP-R-) and GM-CSF to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response.
About RP2
RP2 is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP-R-) and GM-CSF to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP-R- and GM-CSF. RP2 is intended to provide targeted and potent delivery of these proteins to the sites of immune response initiation in the tumor and draining lymph nodes, with the goal of focusing systemic-immune-based efficacy on tumors and limiting off-target toxicity.